Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy

References

• Wood D, Wray R, Poulter N, et al.; for JBS2. Joint British Societies guidelines on prevention of CVD in clinical practice. Heart 2005;91(Suppl V):V1-V521Wood D, Wray R, Poulter N, et al.; for JBS2. Joint British Societies guidelines on prevention of CVD in clinical practice. Heart 2005;91(Suppl V):V1-V52
   PubMedGoogle Scholar
• International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. March 2003.2International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. March 2003.
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–783Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wilson PWF. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992;124:768–744Kannel WB, Wilson PWF. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992;124:768–74
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Stump TE. et al. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J 2006;151: 755e1–755e65Koro CE, Bowlin SJ, Stump TE. et al. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J 2006;151: 755e1–755e6
   Google Scholar
• Superko HR, King S III. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008; 117:560–86Superko HR, King S III. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008; 117:560–8
   PubMed Web of Science ®Google Scholar
• Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975;231:360–817Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975;231:360–81
   PubMed Web of Science ®Google Scholar
• Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94–1148Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94–114
   Web of Science ®Google Scholar
• Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 2005;115:3400–39Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 2005;115:3400–3
   PubMed Web of Science ®Google Scholar
• McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697–70510McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697–705
   PubMed Web of Science ®Google Scholar
• Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 2005;1:317–3111Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 2005;1:317–31
   PubMedGoogle Scholar
• Rubenfire M. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 2004;94:306–1112Rubenfire M. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 2004;94:306–11
   PubMed Web of Science ®Google Scholar
• Paolini JF, Mitchel YB, Reyes R. et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625–3013Paolini JF, Mitchel YB, Reyes R. et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625–30
   PubMed Web of Science ®Google Scholar
• HPS-2/THRIVE: http://www.ctsu.ox.ac.uk/pressreleases/2006- 05-31/hps2-thrive-press-release[Accessed 30/01/2008]14HPS-2/THRIVE: http://www.ctsu.ox.ac.uk/pressreleases/2006- 05-31/hps2-thrive-press-release[Accessed 30/01/2008]
   Google Scholar
• AIM-HIGH: http://accelerator.axioresearch.com/aim-high/[Accessed 30/01/2008]15AIM-HIGH: http://accelerator.axioresearch.com/aim-high/[Accessed 30/01/2008]
   Google Scholar
• NHS. Connecting for Health: MIQUEST. http://www. connectingforhealth.nhs.uk/systemsandservices/data/miquest[Accessed 30/01/2008]16NHS. Connecting for Health: MIQUEST. http://www. connectingforhealth.nhs.uk/systemsandservices/data/miquest[Accessed 30/01/2008]
   Google Scholar
• van Vlymen J. de Lusignan S. A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. Inform Prim Care 2005;13:281–9117van Vlymen J. de Lusignan S. A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. Inform Prim Care 2005;13:281–91
   PubMedGoogle Scholar
• van Vlymen J, de Lusignan S, Hague N. et al. Ensuring the quality of aggregated general practice data: lessons from the Primary Care Data Quality Programme (PCDQ). Stud Health Technol Inform 2005;116:1010–518van Vlymen J, de Lusignan S, Hague N. et al. Ensuring the quality of aggregated general practice data: lessons from the Primary Care Data Quality Programme (PCDQ). Stud Health Technol Inform 2005;116:1010–5
   PubMedGoogle Scholar
• de Lusignan S, Belsey J, Hague N. et al. Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. J Public Health (Oxf) 2006; 28:361–919de Lusignan S, Belsey J, Hague N. et al. Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. J Public Health (Oxf) 2006; 28:361–9
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Russell MW, Huse DM. et al. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J 2000;139:272–8120D’Agostino RB, Russell MW, Huse DM. et al. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J 2000;139:272–81
   PubMed Web of Science ®Google Scholar
• Anderson KM, Odell PM, Wilson PW. et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–9821Anderson KM, Odell PM, Wilson PW. et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–98
   PubMed Web of Science ®Google Scholar
• D’Agostino RBSr, Vasan RS, Pencina MJ. et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 2008;117:743–5322D’Agostino RBSr, Vasan RS, Pencina MJ. et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 2008;117:743–53
   PubMed Web of Science ®Google Scholar
• Joint British Societies Cardiovascular Risk Assessor. http://www.access2information.org:80/health/cvra/[Accessed 04/02/2008]23Joint British Societies Cardiovascular Risk Assessor. http://www.access2information.org:80/health/cvra/[Accessed 04/02/2008]
   Google Scholar
• Tunstall-Pedoe H. The Dundee coronary risk-disk for management of change in risk factors. Br Med J 1991;303:744–724Tunstall-Pedoe H. The Dundee coronary risk-disk for management of change in risk factors. Br Med J 1991;303:744–7
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–100325Conroy RM, Pyorala K, Fitzgerald AP. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Vinogradova Y. et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. Br Med J 2007;335:136–4126Hippisley-Cox J, Coupland C, Vinogradova Y. et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. Br Med J 2007;335:136–41
   PubMed Web of Science ®Google Scholar
• Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172–627Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172–6
   PubMed Web of Science ®Google Scholar
• Reynolds RF, Obermeyer CM. Age at natural menopause in Spain and the United States: results from the DAMES project. Am J Hum Biol 2005;17:331–4028Reynolds RF, Obermeyer CM. Age at natural menopause in Spain and the United States: results from the DAMES project. Am J Hum Biol 2005;17:331–40
   PubMed Web of Science ®Google Scholar
• McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697–70529McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697–705
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ. et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–1530Gordon DJ, Probstfield JL, Garrison RJ. et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15
   PubMed Web of Science ®Google Scholar
• Karas RH, Kashyap ML, Knopp RH. et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008;8:69–8131Karas RH, Kashyap ML, Knopp RH. et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008;8:69–81
   PubMed Web of Science ®Google Scholar
• Guyton JR, Brown BG, Fazio S. et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008;51:1564–7232Guyton JR, Brown BG, Fazio S. et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008;51:1564–72
   PubMed Web of Science ®Google Scholar
• Kamal-Bahl SJ, Burke T, Watson D. et al. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007; 99:530–433Kamal-Bahl SJ, Burke T, Watson D. et al. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007; 99:530–4
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A. et al. Persistence of use of lipid-lowering medications: a cross-national study. J Am Med Assoc 1998;279:1458–6234Avorn J, Monette J, Lacour A. et al. Persistence of use of lipid-lowering medications: a cross-national study. J Am Med Assoc 1998;279:1458–62
   PubMed Web of Science ®Google Scholar
• LaFleur J, Thompson CJ, Joish VN. et al. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006;40:1274–935LaFleur J, Thompson CJ, Joish VN. et al. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006;40:1274–9
   PubMed Web of Science ®Google Scholar
• Compendium of Clinical and Health Indicators. Clinical and health outcomes knowledge base. National statistics 2007. http://tinyurl.com/5l99g4[Accessed 08/04/08]36Compendium of Clinical and Health Indicators. Clinical and health outcomes knowledge base. National statistics 2007. http://tinyurl.com/5l99g4[Accessed 08/04/08]
   Google Scholar
• World Health Organization 2004. Age-standardized death rates from CHD, adults age 0 to 64, by sex, 1972–2005 Europe. http://tinyurl.com/5kh38b[Accessed 08/04/08]37World Health Organization 2004. Age-standardized death rates from CHD, adults age 0 to 64, by sex, 1972–2005 Europe. http://tinyurl.com/5kh38b[Accessed 08/04/08]
   Google Scholar
• Voss R, Cullen P, Schulte H. et al. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002;31:1253–6238Voss R, Cullen P, Schulte H. et al. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002;31:1253–62
   PubMed Web of Science ®Google Scholar
• Brindle P, Emberson J, Lampe F. et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. Br Med J 2003;327:1267–7039Brindle P, Emberson J, Lampe F. et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. Br Med J 2003;327:1267–70
   PubMed Web of Science ®Google Scholar
• Giavarina D, Barzon E, Cigolini M. et al. Comparison of methods to identify individuals at increased risk of cardiovascular disease in Italian cohorts. Nutr Metab Cardiovasc Dis 2007; 17:311–840Giavarina D, Barzon E, Cigolini M. et al. Comparison of methods to identify individuals at increased risk of cardiovascular disease in Italian cohorts. Nutr Metab Cardiovasc Dis 2007; 17:311–8
   PubMed Web of Science ®Google Scholar
• Asia Pacific Cohort Studies Collaboration. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 2007;61:115–2141Asia Pacific Cohort Studies Collaboration. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 2007;61:115–21
   PubMed Web of Science ®Google Scholar
• Brindle PM, McConnachie A, Upton MN. et al. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract 2005;55:838–4542Brindle PM, McConnachie A, Upton MN. et al. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract 2005;55:838–45
   PubMed Web of Science ®Google Scholar
• Tunstall-Pedoe H, Woodward M. By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart 2006;92:307–1043Tunstall-Pedoe H, Woodward M. By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart 2006;92:307–10
   PubMed Web of Science ®Google Scholar
• Luc G, Bard JM, Ferrieres J. et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective epidemiological study of myocardial infarction. Arterioscler Thromb Vasc Biol 2002;22:1155–6144Luc G, Bard JM, Ferrieres J. et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective epidemiological study of myocardial infarction. Arterioscler Thromb Vasc Biol 2002;22:1155–61
   PubMed Web of Science ®Google Scholar